You are here

Category
Technology Name
Briefcase
Scientist
1801
A new image processing tool for transient detection was developed by the group of Prof. Gal-Yam, originally for time-domain observational astronomy.Image sequences are used in various fields, including medical imaging and satellite/airborne imaging. The comparison between images taken at different...

A new image processing tool for transient detection was developed by the group of Prof. Gal-Yam, originally for time-domain observational astronomy.
Image sequences are used in various fields, including medical imaging and satellite/airborne imaging. The comparison between images taken at different conditions (e.g. equipment or configuration, angles, weather and wavelength) can be a highly non-trivial problem, as subtraction artifacts can outnumber real changes between images.
The existing remedy for this problem includes highly complex solutions using machine learning algorithms to narrow the sea of candidates. In some cases, human interpretation of images cannot be avoided, resulting is very long processing times.
The new method presented here provides a proven solution for the subtraction of images taken at varying conditions. The tool can be applied for any type of imaging, allowing fast processing and accurate results.

Applications


  • Satellite/airborne imaging

  • Medical imaging
  • Defect detection

Advantages


  • Fast and automatic

  • Generic, can be applied to various imaging scenarios
  • Easily implementable into existing systems

Technology's Essence


The new method is used for processing at least two N-dimensional data-measurements (DMs) of a physical-property for detecting one or more new-objects and/or a transition of one or more known-objects, in complex constant-background DMs. Generally, the

the method includes: (1) generating a filtered-new-DM by match-filtering a new-DM, respective to impulse response of a reference-DM (2) generating a filtered-reference-DM by match-filtering the reference-DM, respective to impulse response of the new-DM (3) generating an N-dimensional object-indicator (OI) by subtracting the filtered-reference-DM from the filtered-new-DM, or vice versa and (4) generating an N-dimensional data score from the N-dimensional OI, where each of the scores is a probe for existence of an object at a specific N-dimensional location.
+
  • Prof. Avishay Gal-Yam
1722
Our technology provides a new type of oxidative cleavage reaction of organic compounds with highly selective product formation.Polyoxometalate (POM) catalysts have become well-known for their utility and diversity in specific reactions. Through the elucidation of POM catalytic pathways, greater...

Our technology provides a new type of oxidative cleavage reaction of organic compounds with highly selective product formation.
Polyoxometalate (POM) catalysts have become well-known for their utility and diversity in specific reactions. Through the elucidation of POM catalytic pathways, greater versatility has been achieved. This technology is one such application of a novel POM catalyst and is exploited to cleave carbon-carbon double bonds in alkenes (olefins) through an aerobic oxidation reaction. Oxidation reactions are of particular interest because they are difficult to achieve on an industrial scale while maintaining “green” chemistry practices. [1]

--------------------------------------------------------------------------------
[1] Green Chem., 2007, 9, 717-730

Applications


  • As a novel catalyst in industrial organic chemistry processes
  • Sold as a stand-alone catalyst for laboratory or individual use

Advantages


  • Environmentally friendly oxidation reaction
  • Easy catalyst regeneration

Technology's Essence


Our approach is motivated by societal considerations that demand environmentally benign and sustainable solutions for oxidative reactions. As such, we have developed a scheme to react NO2 with a transition-metal-substituted POM which yields a metal-nitro intermediate that is competent for forming the precursors for oxidation with molecular oxygen, O2, to have a final product of ketones and/or aldehydes, and regenerate the POM catalysts.[1]
This method has preference towards di/tri-substituted alkenes. High yields of ketones or aldehydes have been produced and the POM catalyst is regenerated without further oxidation to carboxylic acids, as is typical with other oxidative catalysts.
The selective cleavage of carbon-carbon double or triple bonds with metal-nitro or metal-nitrito compound has not been reported. This exciting new discovery could lead to a wide variety of organic reactions not previously possible, along with revolutionary green oxidative chemistry techniques.

--------------------------------------------------------------------------------
[1] J. Am. Chem. Soc., 2014, 136(31), pp10941-10948 

+
  • Prof. Ronny Neumann
1686

Applications


  • Co-treatment with chemotherapy
  • Co-treatment with statin treatmen

Advantages


  • Lower collateral toxicities allow for greater flexibility in treatment dosage.
  • Enhanced patient survival rate.
  • More favorably considered as a line of therapy due to decreased side effects.
  • Utilization of well-characterized compounds alleviates safety and toxicity considerations.

Technology's Essence


ER stress, elicited by chemotherapeutic agents such as doxorubicin, 5FU, vincristine and bortezomib, or statins such simvastatin, triggers cell death at least in part through generation of leukotriene C4 (LTC4), which induces ROS accumulation, DNA damage and subsequent cell death. LTC4 can be produced by two parallel pathways. Cells of hematopoietic origin express C4 synthase (LTC4S) and secrete their LTC4 load, thereby affecting nearby tissues. In contrast, as discloses by the present invention, non-hematopoietic cells generate LTC4 by the enzyme MGST2 (an isoenzyme of LTC4S), and retain it to act internally leading to their demise. This difference is the basis for the present invention. Thus, LTC4 receptor antagonists (montelukast, pranlukast, etc.) will alleviate the toxicity of chemotherapy towards non-hematopoietic tissues and cells, but retaining the therapeutic effectiveness of chemotherapy on lymphocytic leukemia, lymphoma and myeloma patients. In conjuction, it was found that pranlukast attenuated cell death triggered by a broad range (0.5-4 µg/ml) of simvastatin (a statin) concentrations.

+
  • Prof. Menachem Rubinstein
1665
Improved magnetic resonance imaging (MRI) for cardiac fibrosis and other fibrotic diseases.Myocardial fibrosis is associated with worsening ventricular systolic function, abnormal cardiac remodeling, and increased ventricular stiffness, significantly increasing the risk of adverse cardiac outcomes....

Improved magnetic resonance imaging (MRI) for cardiac fibrosis and other fibrotic diseases.
Myocardial fibrosis is associated with worsening ventricular systolic function, abnormal cardiac remodeling, and increased ventricular stiffness, significantly increasing the risk of adverse cardiac outcomes. Hypertension and diabetes elicit fibrotic processes in the heart, placing a high percentage of the western world population at risk, yet the early identification of fibrotic development in high-risk patients is hindered by lack of adequate fibrosis imaging modalities. This in turn leads to increased morbidity and additional financial burden to health care services. The current standard method to assess myocardial fibrosis employs the usage of MRI coupled with intravenous infusion of Gadolinium contrast agent. However, this method suffers from considerable drawbacks including reduced sensitivity (that permits diagnosis only at advanced stages of disease), lengthy scan times and toxicity of the contrast agent, which excludes a significant subset of patient populations from diagnosis. Thus, the capacity to diagnose myocardial fibrosis in its early stages would allow successful therapeutic intervention, and may also create a platform for the non-invasive study of fibrotic development, thereby facilitating the design of targeted therapies. The current invention is comprised of a novel cardiovascular magnetic resonance method with enhanced sensitivity, without the need for contrast agent administration.

Applications


  • Detection of cardiac fibrosis due to various pathologies, including hypertension, diabetes and heart failure.
  • The method can be applied to detect fibrotic tissues in a broad range of disorders including cancer, renal fibrosis and pathologies related to skeletal muscles.
  • A platform for the clinical study of targeted therapies that may prevent or arrest fibrotic diseases.
  • Monitoring the efficacy of treatment tailored to target fibrotic tissue development.

 


Advantages


  • The method relies on magnetization transfer to provide contrast, and therefore obviates the need for any extrinsic, toxic contrast agent such as Gadolinium.
  • Improved sensitivity over current contrast agent-based cardiac MRI methods.
  • The method can be readily applied to existing MRI clinical imaging systems.

Technology's Essence


A team of researchers at the Weizmann Institute has developed a novel approach for detection of myocardial fibrosis using magnetization transfer contrast (MCT) MRI cardiac imaging technology. The method was tested in vivo on animal models of heart failure and proved highly sensitive for detection of scar tissue formation and monitoring of fibrotic development. One prominent advantage of the present technology over current cardiac imaging modalities is that it eliminates the requirement for extrinsic contrast agents, thereby circumventing potential adverse toxic side effects.

+
  • Prof. Michal Neeman
1758
For patients with AML, identification of their specific subtype and genetic background is crucial for predicting their outlook and decision of treatment. Therefore, understanding the molecular characteristics of specific subtypes of AML can lead to novel therapeutics and improve patient survival.   The...

For patients with AML, identification of their specific subtype and genetic background is crucial for predicting their outlook and decision of treatment. Therefore, understanding the molecular characteristics of specific subtypes of AML can lead to novel therapeutics and improve patient survival.  
The present invention relates to a unique vulnerability of AML subtypes, in which specific chromosome abnormalities result in the dependence of the cancer cells on the activity of native RUNX1. Selective inhibition of RUNX1 under these genetic backgrounds results in killing of the cancer cells.  Thus, the methods described in this innovation may lead to the development of novel AML therapeutics.

Applications


 


Advantages


  • Specificity – targets a signaling vulnerability which is unique to AML and does not occur in healthy cells.
  • Critical impact – the inhibition of RUNX1 in addicted cells induces irreversible killing of the cancer cells by apoptosis rather than just inhibiting their proliferation.
  • Targeting RUNX1 in the addicted AML subtypes can potentially improve patient survival and also be used as a therapy for patients which developed secondary resistance in response to conventional chemotherapy.   

Technology's Essence


The RUNX1 transcription factor is a frequent target of various chromosomal translocations.
The t(8;21) and inv(16) AML subtypes create oncoproteins which interfere with RUNX1 activity in a dominant-negative manner.
While RUNX1 is frequently inactivated in other forms of AML, an active RUNX1 allele is maintained in both t(8;21) and inv(16) AML patients, underscoring the medical significance of native RUNX1 in A-E and C-S mediated leukemogenesis.
Knockdown (KD) of RUNX1 in cell culture models for A-E and C-S showed that these cells are physiologically dependent on RUNX1 activity for their survival and inhibition of RUNX1 in these cells leads to apoptotic cell death. This apoptosis is triggered by decreased expression of key mitosis-regulatory gene.
Therefore, AML subtypes associated with an altered RUNX1 activity or expression are addicted to native RUNX1 for their survival.  Targeting RUNX1 in these patients is expected to activate apoptosis and compromise leukemogenesis.
Thus, the genetic addiction described in the current innovation can be used for the development of novel targeted therapies for AML.

 

+
  • Prof. Yoram Groner
1692
Novel immunosupressive peptides, derived from the TM domain of the HIV protein gp41, with high selectivity towards distinct immune cell populations.Uncontrolled activity of immune cells is an underlying cause of both autoimmune and inflammatory diseases. One of the major challenges in the field is to...

Novel immunosupressive peptides, derived from the TM domain of the HIV protein gp41, with high selectivity towards distinct immune cell populations.
Uncontrolled activity of immune cells is an underlying cause of both autoimmune and inflammatory diseases. One of the major challenges in the field is to develop therapeutics that would target specific populations of immune cells, in order to avoid immune-deficiencies that would leave patients exposed to infections.
The present invention provides novel peptides, based on Immunosupressive regions within the TM domain of the HIV gp41 fusion protein. These peptides were shown to specifically and efficiently inhibit T-cells and TNF? secretion from inflammatory macrophages. Importantly, these peptides were shown to have particular inhibitory effects towards T cells that are activated in a multiple sclerosis model. 

Applications


  • Selective therapy towards T cell mediated autoimmune diseases (e.g. multiple sclerosis)
  • Selective therapy towards TNF?-associated inflammatory disorders

Advantages


  • Specific towards defined cell populations – avoids general immune suppression
  • Significant efficiency towards MS-associated T-cell activation 

Technology's Essence


The present invention takes advantage of the potent immune evasion mechanisms that are utilized as part of the HIV virus pathogenesis. Gp41, a component of the virus envelop, is a transmembrane glycoprotein that mediates viral entry into cells of the immune system. In addition to its role in mediating the actual fusion event, gp41 has been shown to contain immunosuppressive activities that are attributed to its N terminus.
Using biochemical and biophysical approaches, Prof. Shai and his team from the Weizmann institute, reveal yet another immunosuppressive activity of gp41, exerted via its transmembrane domain. Importantly, this immunosupressive activity was shown to be specific for T cell activation (mediated through binding to CD3/TCR complex) and Toll-Like Receptor (TLR)-mediated activation of macrophages.
The present inventors generated synthetic peptides that derive from the gp41 trasmembrane domain and demonstrated their suppressive activity in both in-vitro and in-vivo models.
Significantly, T-cell activation was inhibited following activation with a peptide associated with the propagation of multiple sclerosis (MOG 35-55), proposing a specific inhibitory activity towards MS-generating mechanisms. Macrophages inhibition was shown to significantly compromise the secretion of pro-inflammatory factors, predominantly TNF?, following LTA (lipotechoic acid) activation. 

 

+
  • Prof. Yechiel Shai
  • Prof. Yechiel Shai
1733
The spatial distribution of proteins inside the cell is under tight regulation. This regulation is necessary to ensure proper functioning of the cell, and is of particular importance when extracellular stimulation is applied. Upon stimulation, many signaling proteins rapidly and dynamically change...

The spatial distribution of proteins inside the cell is under tight regulation. This regulation is necessary to ensure proper functioning of the cell, and is of particular importance when extracellular stimulation is applied. Upon stimulation, many signaling proteins rapidly and dynamically change their location. Today, there is a widely recognized need to identify novel sequences which regulates nuclear translocation.
Recently, Prof. Zeger and his team discovered a new level of regulation to stimulated transcription. They showed that ?-like importunes are central mediators of nuclear translocation of signaling proteins. Furthermore they identified the site of interaction and designed accordingly a peptide which was found to prevent nuclear translocation.
This technology presents peptides with the potential of treating inflammatory and immune disease by regulating (prevent or promote) the translocation of proteins into the nucleus.

Applications


  • Inflammation
  • Immune diseases

Advantages


  • Effective
  • Safe

Technology's Essence


The researchers found that ?-like importins play a key role in JNK and p38 translocation. They also found that the translocation of these MAPKs is mediated by the formation of either Imp3/Imp7/MAPK or Imp3/Imp9MAPK heterodimers. Most importantly, the researchers identified the site in p38 that mediate the interaction with Imp7 and Imp9 and showed that the important sequence lies within residues 20-30 of p38?. Subsequently they synthesized a 14 amino acid myristoylated peptide based on the sequence of residues 21-34 of p38?. When it was applied to HeLa cells prior to stimulation, it prevented the nuclear translocation and Imp7/9 interaction of the MAPKs. Since the peptides of this technology are able to specifically inhibit the nuclear activities of p38 (such as inflammatory activities) without modulating their cytoplasmic activities, these peptides may serve as a therapeutic agent for inflammatory and apoptosis related diseases without having side effect.

 

+
  • Prof. Rony Seger
1671
A novel method to revert human iPSC to a fully naive state, retaining stable pluripotency. The feasibility for the existence of ground state naive pluripotency in human embryonic stem cells (hESC) has long been researched. This innovative technology supplies the composition of chemically defined...

A novel method to revert human iPSC to a fully naive state, retaining stable pluripotency. The feasibility for the existence of ground state naive pluripotency in human embryonic stem cells (hESC) has long been researched. This innovative technology supplies the composition of chemically defined conditions required for derivation and long term maintenance of such cells, without genetic modification.
Human naive pluripotent cells can be robustly derived either from already established conventional hESC lines, through iPSC reprogramming of somatic cells, or directly from ICM of human blastocysts. The new human pluripotent state was isolated and characterized; it can open up new avenues for patient specific disease relevant research and the study of early human development.

Applications


  • Reprogramming kits - Somatic cells to iPSC at near 100% efficiency (7days), iPSC to fully naive state.

Advantages


  • Deterministic iPSC reprogramming with no genetic modification required.
  • Stable pluripotency, with low propensity for differentiation
  • Reagents available off-the-shelf.

Technology's Essence


Hallmark features of rodent naive pluripotency include driving Oct4expression by its distal enhancer, retaining a pre-inactivation state of X chromosome in female pluripotent cell lines amongst others. Naive mouse ESCs epigenetically drift towards a primed pluripotent state; while human embryonic stem cells (hESCs) share several molecular features with naive mESCs (e.g. expression of NANOG, PRDM14 and KLF4 naive pluripotency promoting factors), they also share a variety of epigenetic properties with primed murine Epiblast stem cells (mEpiSCs). These observations have raised the question of whether conventioal human ESCs and induced pluripotent stem cells (iPSCs) can be epigenetically reprogrammed into a different pluripotent state, extensively similar with rodent na?ve pluripotency. Researchers at the Weizmann Institute discovered that supplementation of certain chemically defined conditions, synergistically facilitates the isolation and maintenance of pluripotent stem cells that retain growth characteristics, molecular circuits, a chromatin landscape, and signaling pathway dependence that are highly similar to naive mESCs, and drastically distinct from conventional hESCs.

+
  • Dr. Jacob (Yaqub) Hanna
1772
MTCH2 as a novel target for the treatment of obesity.Obesity is an escalating public health problem with an increasing prevalence worldwide, and a primary contingency of many life-threatening diseases, as well as early mortality. In the U.S. alone, more than one-third of adults are obese. Obesity-...

MTCH2 as a novel target for the treatment of obesity.
Obesity is an escalating public health problem with an increasing prevalence worldwide, and a primary contingency of many life-threatening diseases, as well as early mortality. In the U.S. alone, more than one-third of adults are obese. Obesity-related conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some of the leading causes of preventable death. Physicians and patients alike consider the weight-loss efficacy of the current therapeutics to be unsatisfactory. Therefore, there is an unmet need for innovative options that are at once safe and efficacious, and allow the patient to maintain weight loss.
The present invention describes the identification of Mitochondrial Carrier Homolog 2 (MTCH2) as a novel player in muscle metabolism and the therapeutic potential of inhibiting MTCH2 for the treatment of diet-induced obesity and diabetes.

Advantages


  • A fresh approach for targeting weight-related disorders
  • Direct effect on metabolism instead of indirect mechanisms of current therapeutics which target appetite modulation.
  • Protection from diet-induced obesity can be used as a prevention treatment for people with a tendency for weight gain.  

Technology's Essence


MTCH2 functions as a receptor-like protein for the pro-apoptotic BID protein in the mitochondria.
MTCH2 was identified as one of six new gene loci associated with Body Mass Index (BMI) and obesity in humans suggesting that MTCH2 may also play a role in metabolism.
MTCH2 was recently shown by the Gross’s lab to also function as a repressor of   mitochondria oxidative phosphorylation (OXPHOS) in the hematopoietic system.
Deletion of MTCH2 in skeletal muscle increases mitochondrial OXPHOS and mass, and increases capacity for endurance exercise. In addition, loss of MTCH2 increases mitochondria and glycolytic flux in muscles as measured by monitoring pyruvate and lactate levels.
MTCH2 knockout mice are protected from diet-induced obesity, hyperinsulinemia, and are more prone to weight loss upon caloric restriction.
Therefore, the association of MTCH2 with mitochondrial function offers a potential novel target for muscle metabolism modulation in the fight against metabolic disorders such as obesity and diabetes.

 

+
1704
Neuropathic Gaucher’s (nGD), is a rare but very severe manifestation of the disease, with a varying degree of involvement of the central nervous system, in addition to systemic symptoms. As of today, there is no cure for these severe conditions. The search for such cure is tremendously hindered by the...

Neuropathic Gaucher’s (nGD), is a rare but very severe manifestation of the disease, with a varying degree of involvement of the central nervous system, in addition to systemic symptoms. As of today, there is no cure for these severe conditions.
The search for such cure is tremendously hindered by the unmet need for a reliable biochemical biomarker for nGD.
The present invention identifies the glycoprotein non-metastatic B (GPNMB) as a potential powerful nGD biomarker for use in early diagnosis, determination of disease severity, as well as a straight forward readout in clinical and preclinical experiments.

Applications


Diagnosis and drug development for neuropathic GD

Advantages


Straight forward diagnostic tool – based on standard biochemical assays
Relatively simple clinical procedure – samples are collected from CSF and not brain
High sensitivity – for the diagnosis of disease severity
Compatible with preclinical experiments

Technology's Essence


Prof. Futerman and his team preformed a quantitative global proteomic analysis (using LC-MS/MS) of cerebrospinal fluid (CSF) samples from four patients with Type 3 GD, to identify mis-regulated proteins, compared with healthy subject.
Glycoprotein non-metastatic B (GPNMB), a protein that was previously associated with several lysosomal storage disorders, exhibited very high levels (a 42-fold increase) in the CSF of type 3 GD patients.  Two peptides were identified from GPNMB, both located in the non-cytosolic domain, suggesting that GPNMB is cleaved and secreted into the CSF from the brain. LC-MS/MS results were validated by ELISA and by western blot analysis in CSF and in human brain samples.
Several proof of principle experiments were conducted in order to prove the validity of using GPNMB as a biomarker for monitoring disease state and treatments efficacy in neuropathic GD in patients and mouse models:
GPNMB levels were shown to be correlated with the severity of type 3 Gaucher’s disease patients, as measured by lower IQ score and lower score in Purdue Pegboard test, assessing eye-hand coordination. In addition, using conduritol b epoxide (CBE)-injection based mouse model that simulate different severities and recovery periods, it was shown that GPNMB levels rapidly rise or decline to reliably reflect progress/remission states of the diseases.

+
  • Prof. Anthony H. Futerman
1749
Our novel technology provides an inexpensive, safe and clean solution for loading and unloading of hydrogen on demand with high potential hydrogen storage capacity. Hydrogen storage is currently the key hurdle to its utilization as an alternative green fuel. Being the smallest molecule, hydrogen is...

Our novel technology provides an inexpensive, safe and clean solution for loading and unloading of hydrogen on demand with high potential hydrogen storage capacity.
Hydrogen storage is currently the key hurdle to its utilization as an alternative green fuel. Being the smallest molecule, hydrogen is highly diffusive and buoyant. Currently, hydrogen is stored physically as a gas, requiring high-pressure tanks, or in liquid form at cryogenic temperatures, both methods require high energy input. Proposed chemical storage systems are based on relatively expensive materials, suffer from poor regeneration after hydrogen release and require elevated temperatures and pressures.
The presented technology utilizes inexpensive and abundant organic compounds that generate hydrogen gas during a chemical transformation. Hydrogen release and the regeneration of the original compound are performed in mild conditions using the same catalyst. This system is a promising candidate to be the basis of compact and cost-effective chemical hydrogen storage platforms.

Applications


  • High potential hydrogen storage capacity (6.6 wt%)
  • Inexpensive and readily available hydrogen carriers (aminoalcohols)
  • Relatively mild release and regeneration conditions

  • Advantages


    • Hydrogen-fueled systems, including fuel cells
    • High capacity hydrogen storage systems

    Technology's Essence


    The technology is based on aminoalcohols that are catalytically converted to cyclic dipeptides, while forming hydrogen gas, using a ruthenium pincer catalyst. Peptide hydrogenation, using the same catalyst, regenerates the aminoalcohol. The same method can be applied with diaminoalkanes and alcohols as well.
    The reaction requires a relatively low organic solvent volume, a catalytic amount of base (KOtBu) for the in situ generation of the active catalyst and mild reaction conditions in terms of hydrogen pressure (50 bar) and temperature (~100 oC). Repetitive cycles of the dehydrogenation-hydrogenation reactions can be performed without adding new catalyst, while maintaining high percentages of aminoalcohol conversion.

    +
    • Prof. David Milstein
    1676
    A novel renewable energy method for storage of concentrated solar power (CSP) thermal energy directly to electrochemical energy that can be used for for distribution.A crucial issue for CSP technologies today is providing energy capable of dispatchable generation, that is, sources of electricity whose...

    A novel renewable energy method for storage of concentrated solar power (CSP) thermal energy directly to electrochemical energy that can be used for for distribution.
    A crucial issue for CSP technologies today is providing energy capable of dispatchable generation, that is, sources of electricity whose power load can be changed instantaneously with power demand. Further commercial deployment of CSP on a large scale depends on increase of the annual contribution of solar electricity, better coping with the intermittent nature of this resource and rapid integration with existing electrical distribution infrastructure, i.e. smart grids. 
    The technology presented here offers a unique solution to these problems while significantly reducing monetary and environmental costs associated with current CSP systems.
    Unlike conventional thermal CSP plants, the novel method does not require the use of a turbine to convert heat to electricity, and the electricity is directly obtained from the electrochemical cell during its discharge cycle. Moreover, this energy storage technique precludes the use of electric power generators (e.g. turbines, wind turbines, photovoltaic panels) which are often used to recharge electrochemical cells by applying electrical power to the cells' electrode terminals. This reduces expenses and eliminates inefficiencies of a traditional solar electrical plant.

    Applications


    • As modular stand-alone electrical plant for commercial or private use.
    • Integrate into existing power plants for load sharing.

    Advantages


    • Directly transform solar thermal energy into electrical potential energy.
    • Transport of large amounts of water in arid areas is not required.
    • Battery can change loading instantaneously for:
      - Use in smart grid and dispatchable generation
      - Easily Incorporated with other green energy solutions

    Technology's Essence


    This novel system utilizes a rechargeable thermochemical cycle based on Na-S battery technology. The innovation is the exploitation of concentrated solar radiation for thermo-chemical charging instead of electricity from photovoltaic or wind resources as done today. With this concept, a final efficiency of about 50% from solar to electricity can be achieved, which makes a monumental economic impact on existing CSP technologies. The sodium-sulfur battery discharge cycle usually works at temperatures ranging between 300 and 350oC, at which the sodium, sulfur and the reaction product of sodium polysulfide, Na2Sx (where x=3 to 5), exist in their liquid state. Charging of the battery is achieved at temperatures of 1500-1700 oC, when sodium polysulfide is fully decomposed and the full electrical potential of the battery is restored.[1] Instead of charging the Na-S Battery with an external source of electricity to decompose the sodium polysulfide compound back to its Na and S ingredients, it is proposed that the decomposition process will be achieved thermally via CSP.

    +
    • Mr. Michael Epstein
    1782
    L-DOPA is a high value compound used in the treatment of Parkinson’s disease and a precursor for other high value compounds. Current industrial methods for producing L-DOPA are problematic in terms of complexity, yield, or toxic byproducts.Betalains are robust, flavorless, natural water soluble dyes,...

    L-DOPA is a high value compound used in the treatment of Parkinson’s disease and a precursor for other high value compounds. Current industrial methods for producing L-DOPA are problematic in terms of complexity, yield, or toxic byproducts.
    Betalains are robust, flavorless, natural water soluble dyes, in the color ranges of both red-violet and yellow-orange. Currently there is no natural quality source for water soluble natural yellow dyes, with present natural yellow dyes being water insoluble.
    The present technology offers an alternative method that is simple, does not produce side-products, and is non-toxic with Tyrosine being the only feedstock. The technology produces L-DOPA and natural water soluble yellow and red Betalain dyes, both within yeast and in different plant species.

    Applications


    • Production of L-DOPA for use in pharmaceuticals or dietary supplements.
    • Synthesis of water soluble yellow and red natural dyes for use as colorants, antioxidants, and food supplements.
    • Altering coloration of ornamental plants by inserting the metabolic pathway.

    Advantages


    • One-step reaction for L-DOPA synthesis from Tyrosine.
    • Non-toxic and non-hazardous synthesis.
    • Ecologically friendly - no waste management issues.
    • Multiple colors can be produced with yellow, red, or orange if pathways combined.
    • Flavorless - avoid influencing the taste of different products.
    • Flexibility in biosynthetic production - multiple possible host systems.
    • Specificity - no side products produced
    • Mild Conditions - enzyme(s) requires ambient temperatures.

    Technology's Essence


    The present technology takes advantage of the Betalain biosynthetic pathway to selectively produce L-DOPA and natural Betalain dyes. A newly discovered, specific, cytochrome P450-CYP76AD6 begins the pathway, with the capacity to convert Tyrosine to L-DOPA. Then L-DOPA is converted to Betalamic acid via DOPA 4, 5-dioxygenase.
    With the Betalamic acid intermediate, the biosynthetic pathway diverges to make either Betaxanthins (yellow dyes) or Betacyanins (red dyes). In the production of yellow dyes an amine (e.g. amino acid) spontaneously reacts with Betalamic acid. In the case of red dyes, cycloDOPA (generated by the enzyme CYP76AD1 modifying Tyrosine and L-DOPA) and a Betalain-related glucosyltransferase react with Betalamic acid. Furthermore the two pathways can be done in parallel to produce an orange color.

     

    +
    • Prof. Asaph Aharoni
    1712
    • Prof. Yechiel Shai
    1751
    Many cancer cells hijack and remodel existing metabolic pathways for their benefit. Specific targeting of these metabolic dependencies offers cancer patients increased efficiency and minimized side effects. Yet, the complexity of these pathways hinders the identification of targets. The present...

    Many cancer cells hijack and remodel existing metabolic pathways for their benefit. Specific targeting of these metabolic dependencies offers cancer patients increased efficiency and minimized side effects. Yet, the complexity of these pathways hinders the identification of targets.
    The present discovery elucidates the pathway by which argininosuccinate synthase (ASS1) down-regulation confer cancer progression. It shows that decreased activity of ASS1 in cancers supports proliferation by linking excess aspartate to pyrimidines synthesis. Importantly, these studies highlight Citrin (a mitochondrial aspartate transporter) inhibition as a potential method to decrease aspartate levels and selectively target this metabolic pathway in ASS1 depleted cancers.

    Applications


    • Targeted Treatment for ASS1 depleted cancers.

    Advantages


    • Targeted therapy, against a well defined pathway, increases the prospects for success.
    • Selective – targeting cancer metabolic dependency minimizes the chances for healthy cells damage that lead to side effects.

    Technology's Essence


    Cancer cells hijack and remodel existing metabolic pathways for their benefit in what is termed the Warburg effect. Researchers from Dr. Ayelet Erez's lab, at the Weizmann institute of Science, have delineated the metabolic benefit(s) conferred by loss of ASS1 to cancers. In agreement with previous experience, they found that ASS1 deficiency has an additional arginine- independent effect that is directly related to its substrate, aspartate.
    By focusing on the relevant physiological and pathological model systems, it was found that ASS1 deficiency-mediated increase in aspartate levels lead to excessive proliferation through pyrimidine synthesis. The link between the two is provided by CAD (carbamoyl-phosphate synthase 2, aspartate transcarbamylase, dihydroorotase complex) and the mTOR signaling pathway.
    Importantly, the present inventors have found that blocking Citrin, the mitochondrial aspartate transporter, rescues cell proliferation by reducing aspartate levels. Citrin may thus serve as a strong candidate for targeted therapy of ASS1 depleted cancers.   
    Supporting this model, retrospective survival analysis of several cancers reveal that cancers with both decreased ASS1 expression and high Citrin levels have a trend for significantly worse prognosis.

    +
    • Dr. Ayelet Erez

    Pages